基于DLC1基因的抑制肿瘤的药物研究状况  

Current situation of the advance in tumor suppression drugs based on DLC1 gene

作　　者：刘芷兮 陈燕 黄婷文丽 肖洪涛 LIU Zhi-xi;CHEN Yan;HUANG Ting-wen-li;XIAO Hong-tao(Department of Clinical Pharmacy,Sichuan Cancer Hospital·Institute,Sichuan Cancer Prevention and Treatment Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan Province,China;Personalized Drug Therapy Sichuan Key Laboratory,Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川省肿瘤医院·研究所、四川省癌症防治中心,电子科技大学医学院临床药学部,四川成都610041 [2]个体化药物治疗四川省重点实验室,四川成都610041

出　　处：《中国临床药理学杂志》2021年第18期2515-2519,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家临床药学重点专科建设基金资助项目(30305030698);四川省卫生厅基金资助项目(100491,120111,17Z0038);四川省人民医院青年基金资助项目(30305030606,30305030859);四川省科技厅基金资助项目(2014FZ0103,2015JQO27,2015ZR0160);四川省科技厅基金资助项目(2020YFS0412);四川省青年科技创新研究团队基金资助项目(2020JDTD0029);四川省肿瘤医院·研究所资助项目(YB2019001)。

摘　　要：抑癌基因DLC1基因最开始在肝癌细胞中发现缺失,然后依次发现在多种实体肿瘤中缺失。通过基因治疗手段治疗由DLC1基因缺失引起的肿瘤是未来的研究方向。DLC1基因表达在癌细胞中经常沉默或下调的主要原因是启动子甲基化或等位基因缺失和基因点突变等。本文从作用机制方面对现有的作用于DLC1的药物:黄酮、白藜芦醇、地西他滨和姜黄素等进行了综述。The deleted in liver cancer1(DLC1)gene is a tumor suppressor gene,which was first found in liver cancer cells,and then found in various solid tumors.Gene therapy for tumors caused by DLC1 gene deletion is the future research direction.It has been reported that the main reasons for frequent silencing or down-regulation of DLC1 gene expression in cancer cells are promoter methylation or allele deletion and gene point mutation,etc.In this paper,the existing drugs acting on DLC1,such as flavonoids,resveratrol,decitabine,nuclear YAP inhibitor and curcumin,are reviewed from the mechanism of action,and the future development trend of these drugs is prospected.

关 键 词：抑癌 结构域 启动子甲基化 上调 

分 类 号：R979.1[医药卫生—药品]